Neogen Issues Voluntary Nationwide Recall of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution
MWN-AI** Summary
Neogen Corporation (NASDAQ: NEOG) recently announced a voluntary nationwide recall of all lots of Neogen® Vet HYCOAT® Hyaluronate Sodium Sterile Solution. This product, intended for use in dogs, cats, and horses, is being recalled due to microbial contamination found in certain 10 mL/50 mg product vials. There have been reports of adverse events in horses after intraarticular injections with this solution, which goes against its labeled intended use. However, Neogen has not received adverse event reports when the product is used as directed.
In light of these findings and in a precautionary measure, the company is also recalling the 2 mL/20 mg vials. Neogen is collaborating with the FDA during this ongoing investigation. The recalled lots, marketed as sterile, cannot be considered safe due to contamination risks that could lead to infections in animals, especially when misused as intraarticular injections or in surgical wound treatments.
The affected product comes in two sizes: 2 mL/20 mg and 10 mL/50 mg, with specific lot numbers identified for recall. Neogen is actively contacting distributors and customers via email to facilitate the return of all affected products. They are advising customers to stop using the recalled products and quarantine them.
For inquiries, customers can reach Neogen Animal Safety Customer Support, and veterinarians experiencing related issues are encouraged to report them to the FDA. This recall does not impact any other Neogen products. Neogen is committed to advancing safety and efficacy through its product offerings in the food safety and veterinary sectors.
MWN-AI** Analysis
Neogen Corporation's (NASDAQ: NEOG) recent voluntary recall of its HYCOAT® Hyaluronate Sodium Sterile Solution raises significant concerns for investors, particularly regarding potential implications for its stock performance and market perception. The recall affects all lots within expiry distributed nationwide due to microbial contamination, which poses risks if misused, particularly through intraarticular injections.
The immediate market reaction could exhibit volatility in Neogen's stock, as recalls often spark investor apprehension about potential liability, regulatory scrutiny, and impacts on sales. The proactive approach by Neogen to cooperate with the FDA and initiate a recall indicates the company is focused on safety, which could mitigate some backlash. However, the recall's timing is crucial; if it coincides with a period of already weakened sentiment in the animal health sector, this could exacerbate any negative reaction from shareholders.
Investors should closely monitor Neogen's handling of the recall, especially their communication strategies and effectiveness in managing customer relations. Transparency in their investigation outcomes and quick resolution of the issue will be key to restoring confidence. Additionally, the company’s diversified portfolio in food safety and other animal health products can serve as a buffer during this tumultuous period but should be monitored for any impact on future earnings guidance.
Long-term investors may view this as a temporary setback, provided Neogen can return to normal operations swiftly and effectively. Short-term traders, however, should remain cautious; a thorough analysis of the ongoing developments, sales figures post-recall, and market trends in veterinary products will be essential in making informed decisions. Potential accumulation of positions at lower prices might be appealing if the fundamental outlook remains strong post-recall.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Neogen Corporation (NASDAQ: NEOG) is voluntarily recalling all lots within expiry of Neogen ® Vet HYCOAT ® Hyaluronate Sodium Sterile Solution, for use in dogs, cats, and horses, to the veterinarian level. Neogen distributes this product, which is manufactured by a third-party supplier. This recall has been initiated due to microbial contamination in certain lots of 10 mL/50 mg product vials. Neogen received a number of reports of adverse events in horses following intraarticular injections of this product, which is inconsistent with its labeled, intended use. To date, Neogen has not received reports of adverse events when used in a manner consistent with the labeled use.
While the company’s investigation into this issue is ongoing, out of an abundance of caution the 2mL/20mg product vials are also being recalled. The company is proactively working with the FDA on this matter.
Risk Statement: This product is labeled as a sterile solution, but due to microbial contamination of certain lots, the recalled lots should no longer be considered sterile. Vials that contain a microbial contaminant potentially result in infection in the animal. The risk is particularly acute when used as an intraarticular injection (which is inconsistent with its labeled, intended use). There also is risk if used according to the label as a topical wound management system in surgical wounds, burns, ulcers, and autograft procedures. To date, Neogen has not received reports of adverse events when used in a manner consistent with the labeled use.
The product is intended for use as a topical wound management system and is packaged in vials of 2mL/20 mg (UPC Code 726087089386) and 10mL/50mg (UPC Code 726087089393).
The subject product lots within expiry include the following:
2 mL/20 mg lot numbers: 0236735, 0236736, 0336746, 0336747, 0536760, 0536761, 0636768, 0636769, 0836792, 0836785, 0836788, 0836789, 0936794, 0936795, 1036801, 1036802, 1036803, 1036804, 1136807, 1136808, 0246837, 0246838, 4L001B, 4L002
10 mL/50 mg lot numbers: 0136731, 0736777, 0346843, 5A001
Neogen ® Vet HYCOAT ® Hyaluronate Sodium Sterile Solution was distributed nationwide to animal health distributors and veterinarians.
Neogen is notifying its distributors and direct customers by email and is arranging for return of all recalled products. Anyone that has HYCOAT which is being recalled should discontinue use and quarantine product.
Customers with questions regarding this recall can contact Neogen Animal Safety Customer Support Monday through Friday, 8AM-5PM ET at 859-254-1221 or via email at AnimalHealth@neogen.com for return shipping instructions. Customers can work through their distributor for product returns.
Veterinarians that have experienced any problems that may be related to using this product should report to the FDA's Center for Veterinary Medicine on FORM FDA 1932a, “Veterinary Adverse Experience, Lack of Effectiveness or Product Defect Report.”
- Download and submit Form FDA 1932a available at https://www.fda.gov/reportanimalae , or
- Contact FDA at 1-888-FDA-VETS to request this form.
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
No other Neogen products are affected by this field action.
About Neogen
Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260128021369/en/
FAQ**
How is Neogen Corporation (NASDAQ: NEOG) addressing the adverse events reported in horses related to the recall of the HYCOAT® Hyaluronate Sodium Sterile Solution, and what measures are being implemented to regain trust with veterinarians?
In light of the microbial contamination issues that led to the recall, what steps is Neogen Corporation (NASDAQ: NEOG) taking to ensure the quality and safety of products manufactured by third-party suppliers in the future?
What impact might the voluntary recall of Neogen Corporation's (NASDAQ: NEOG) HYCOAT® product have on the company's financial performance and stock price in the coming quarters?
How is Neogen Corporation (NASDAQ: NEOG) collaborating with the FDA during this recall process, and what updates can we expect regarding the investigation and resolution of the issue?
**MWN-AI FAQ is based on asking OpenAI questions about Neogen Corporation (NASDAQ: NEOG).
NASDAQ: NEOG
NEOG Trading
-6.33% G/L:
$8.96 Last:
1,026,605 Volume:
$9.45 Open:
